The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced
mucositis: a double-blind, randomized, placebo-controlled study.
Author(s): Mansouri A, Hadjibabaie M, Iravani M, Shamshiri AR, Hayatshahi A, Javadi MR,
Khoee SH, Alimoghaddam K, Ghavamzadeh A.
Affiliation(s): Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran,
Iran.
Publication date & source: 2012, Hematol Oncol. , 30(1):22-6
The purpose of this study was to evaluate the effect of oral zinc sulfate in the
prevention of chemotherapy-induced mucositis in patients undergoing hematopoietic
stem-cell transplantation (HSCT). This study was a double-blind, randomized,
placebo-controlled design, with 60 patients undergoing HSCT, divided
proportionally in experimental group who received zinc sulfate, and in placebo
group. They all had received high-dose chemotherapy conditioning regimen for
allogenic transplantation. Oral mucositis assessed was based on World Health
Organization (WHO) oral mucositis scale. There were no significant differences in
the development of mucositis between the two groups. Severity of mucositis was
not significantly different between the two groups either. The same result was
obtained regarding the duration of mucositis. Zinc sulfate did not show any
significant adverse effects in experimental group. In conclusion, Zinc sulfate
did not have any clinical benefits in prevention or reduction of severity, and
duration of high-dose chemotherapy-induced mucositis in patients undergoing HSCT.
|